Background
Background evidence
Trial objectives
Hypotheses
Primary hypothesis
Secondary hypotheses
Methods/Design
Study design and plan
Ethics and trial registry
Recruitment
-
A dedicated study website
-
Advertisements in local newspapers and radio
-
A press release which may involve featured articles in newspapers and appearances by the chief investigator on radio and TV
-
Online advertisements, including the Swinburne University ‘Participate in Research’ webpage (http://www.swinburne.edu.au/lss/chp/projects/kava.html) and the websites of local anxiety disorder organisations (for example, Anxiety Disorders Association of Victoria, Anxiety Recovery Centre Victoria), Google, and Facebook
-
Posters and brochures displayed on campus and in the waiting rooms of local Healthscope pathology centres and medical clinics
Primary outcome measure
Secondary outcome measures
-
In addition, the Beck Anxiety Inventory (BAI) will be used as a participant self-report scale to assess anxiety levels. It consists of 21 items ranging from 0 (not present) to 3 (severe). These items are more somatically orientated than the SIGH-A and provide additional information on anxiety outcomes.
-
The Penn State Worry Questionnaire (PSWQ) is a 16-item self-report measure of the intensity and excessiveness of worry. Examples of items are “Many situations make me worry” and “Once I start worrying, I cannot stop.” Participants rate items on a 5-point Likert scale from 1 (“Not at all typical of me”) to 5 (“Very typical of me”). Total scores range from 16 to 80, with higher scores indicating pathological worry. The PSWQ is widely used and has shown good to very good internal consistency, test-retest reliability, and discriminant validity for GAD versus other anxiety disorders [49].
-
Mood will be assessed at each visit using the SIGMA (Structured Interview Guide for the Montgomery–Åsberg Depression Rating Scale (MADRS)), a diagnostic questionnaire which measures severity of depression symptoms. The SIGMA provides structured questions for each item to ensure standardisation of administration. Each item yields a score of 0 to 6, producing an overall score ranging between 0–60. A higher MADRS score indicates more severe depression. Inter-rater reliability with the SIGMA is reported to be excellent (r = 0.93) [50]. The use of this scale is important, as sufferers of GAD often have co-morbid depression, which may affect their response to treatment.
-
Quality of life/life stressor measures will be administered at selected visits. The WHOQOL-BREF measure is a reduced version of the original instrument, designed for clinical trial use. It comprises 26 items, covering the domains of physical health, psychological health, social relationships, and environment. The Social Readjustment Rating Scale (SRRS) is a scale using ‘Life Change Units’ (LCUs) to quantify the number and severity of life stressors occurring in the preceding 12-month period. Both will be administered at baseline and at week 16. The Kessler Psychological Distress Scale (K10) is a 10-item questionnaire designed to obtain a global measure of perceived stress level, with questions pertaining to anxiety and depressive symptoms experienced in the past four-week period. For this study it will be administered at each visit.
-
The Arizona Sexual Experiences Scale (ASEX) will be employed to assess the effects of kava on participants’ sexual functioning. Specifically, the self-report scale explores effects on desire, arousal level, and physiological responses over the course of the past week. It consists of five self-report items, each rated on a 6-point scale. Total scores can range between 5–30, where higher scores indicate greater sexual dysfunction. The use of this scale is important, as conventional SSRI antidepressant treatments (used to treat GAD) commonly cause sexual side effects, and results of a previous study [37] showed a significant improvement in sex drive for women. If this finding is replicated, it will show a point of difference between kava and conventional treatments. Due to the sensitive nature of the items, completion of this scale is optional.
-
The Swedish Universities Scales of Personalities (SSP) is a 91-item self-rated questionnaire based on the Karolinska Scales of Personality (KSP), a scale designed to measure stable personality traits related to psychopathology [51]. It assesses four general temperament dimensions: anxiety, extraversion, socialization, and aggression. This questionnaire will be given to participants after their initial baseline visit to complete in their own time and return at the next visit.
-
Genotyping of candidate and haplotype-tagging single nucleotide polymorphisms in monoamine, glutaminergic, and GABA transporter genes, measured via blood sample at week 1, will be achieved using a Sequenom Mass-Array.
-
A custom RT2 PCR Array (Qiagen) will be used to examine gene expression of candidate genes (Table 1) at weeks 1 and 8.Table 1Gene expression listGene symbolGene nameGABBR1GABA, B receptor 1GABBR2GABA, B receptor 2GABRA1GABA, A receptor, alpha 1GABRA2GABA, A receptor, alpha 2GABRA4GABA, A receptor, alpha 4GABRA5GABA, A receptor, alpha 5GABRA6GABA, A receptor, alpha 6GABRB1GABA, A receptor, beta 1GABRB3GABA, A receptor, beta 3GABRDGABA, A receptor, deltaGABREGABA, A receptor, epsilonGABRG1GABA, A receptor, gamma 1GABRG2GABA, A receptor, gamma 2GABRG3GABA, A receptor, gamma 3GABRQGABA, A receptor, thetaGABRR1GABA, A receptor, rho 1GABRR2GABA, A receptor, rho 2ADCY7Adenylate cyclase 7ADORA1Adenosine A1 receptorADORA2AAdenosine A2a receptorCACNA1ACalcium channel, voltage-dependent, P/Q type, alpha 1A subunitCACNA1BCalcium channel, voltage-dependent, N type, alpha 1B subunitGNAI1G protein, alpha inhibiting activity polypeptide 1GNAQG protein, q polypeptideGPHNGephyrinSNCASynuclein, alphaNSFN-ethylmaleimide-sensitive factorP2RX7Purinergic receptor P2X, ligand-gated ion channel, 7SLC1A3Glial high affinity glutamate transporterSLC32A1Solute carrier family 32 (GABA vesicular transporter), member 1SLC38A1Solute carrier family 38, member 1SLC6A1Solute carrier family 6 (neurotransmitter transporter), member 1SLC6A11Solute carrier family 6 (neurotransmitter transporter), member 11SLC6A12Solute carrier family 6 (neurotransmitter transporter), member 12SLC6A13Solute carrier family 6 (neurotransmitter transporter), member 13ABAT4-aminobutyrate aminotransferaseALDH5A1Aldehyde dehydrogenase 5 family, member A1GAD1Glutamate decarboxylase 1GLSGlutaminaseGLULGlutamate-ammonia ligasePHGDHPhosphoglycerate dehydrogenaseDRD1Dopamine receptor D1DRD2Dopamine receptor D2DRD3Dopamine receptor D3DRD4Dopamine receptor D4DRD5Dopamine receptor D5COMTCatechol-O-methyltransferaseDBHDopamine beta-hydroxylaseDDCDopa decarboxylaseMAOAMonoamine oxidase ATHTyrosine hydroxylaseSLC6A3Solute carrier family 6 (dopamine transporter), member 3SLC6A4Solute carrier family 6 (serotonin transporter), member 4MAOBMonoamine oxidase BHTR1ASerotonin receptor 1AGRIA1Glutamate receptor, ionotropic, AMPA 1GRIA2Glutamate receptor, ionotropic, AMPA 2GRIA3Glutamate receptor, ionotropic, AMPA 3GRIA4Glutamate receptor, ionotropic, AMPA 4GRIK1Glutamate receptor, ionotropic, kainate 1GRIK2Glutamate receptor, ionotropic, kainate 2GRIK4Glutamate receptor, ionotropic, kainate 4GRIK5Glutamate receptor, ionotropic, kainate 5GRIN1Glutamate receptor, ionotropic, N-methyl D-aspartate 1GRIN2AGlutamate receptor, ionotropic, N-methyl D-aspartate 2AGRIN2BGlutamate receptor, ionotropic, N-methyl D-aspartate 2BGRIN2CGlutamate receptor, ionotropic, N-methyl D-aspartate 2CGRM1Glutamate receptor, metabotropic 1GRM2Glutamate receptor, metabotropic 2GRM3Glutamate receptor, metabotropic 3GRM4Glutamate receptor, metabotropic 4GRM5Glutamate receptor, metabotropic 5GRM6Glutamate receptor, metabotropic 6GRM7Glutamate receptor, metabotropic 7GRM8Glutamate receptor, metabotropic 8ADRA1AAdrenoceptor alpha 1AADRA1DAdrenoceptor alpha 1DADRA2AAdrenoceptor alpha 2AADRB2Adrenoceptor beta 2ADRB3Adrenoceptor beta 3SLC18A2Vesicular monoamine transporterSLC6A2Norepinephrine transporterCYP3A4Cytochrome P450 3A4CYP2D6Cytochrome P450 2D6CYP2E1Cytochrome P450 2E1ARAndrogen receptorNRG1Neuregulin-1BDNFBrain-derived neurotrophic factorABCG2Breast cancer resistance proteinABCB1P-glycoproteinGAPDHReference genesSADHReference genesB2MReference genes
-
Anterior cingulate cortical (ACC) region metabolite profiles, including N-acetyl-l-aspartate (NAA), creatine (Crn), glutamate/glutamine (Glu/Gln), and gamma-amino butyric acid (GABA), will be measured using single voxel magnetic resonance spectroscopy (MRS) at weeks 1 and 8.
-
ACC region activity at rest and functional connectivity network (that is, default mode network) will be analysed using resting-state functional magnetic resonance imaging (fMRI) at weeks 1 and 8.
-
ACC region task-dependent activation levels associated with anticipatory anxiety will be assessed using task fMRI (the International Affective Picture System (IAPS; [52]) at weeks 1 and 8.
-
Acute anxiety levels related to undergoing scanner session at weeks 1 and 8 will be measured on the Spielberger State-Trait Anxiety Inventory — Trait and State components [53].